Santen Corporate (en)

Santen Obtains Marketing Approval in Republic of Korea for STN1012700 (Ryjusea 0.25mg/mL Ophthalmic Solution), an Ophthalmic Solution to Slow the Progression of Myopia

November 2, 2026 – Osaka, Japan – Santen Pharmaceutical Co., Ltd. (hereinafter “Santen”), announced today that it has received marketing approval in the Republic of Korea for STN1012700 (Ryjusea 0.25mg/mL Ophthalmic Solution), an ophthalmic solution indicated to slow the progression of myopia. This marks the second marketing approval for the product in Santen’s Asia business region*, following the Philippines.

In Japan, the product has been available since April 2025 under the brand name Ryjusea® Mini Ophthalmic Solution 0.025%. STN1012700 is a preservative-free, unit-dose ophthalmic solution, designed to provide consistent dosing and support safe, long-term use primarily in children. The efficacy of this product is based on the results  from ORANGE,　a Phase II/III placebo-controlled, double-masked clinical study conducted in Japan.

Myopia is projected to affect 39.9% of the global population by 2030 and 49.8% by 2050. 1 The recent increase in myopia is believed to be attributable to lifestyle changes, particularly a combination of a decrease in the amount of time children spend outdoors and an increase in near-work activities—such as reading, studying, and using digital devices—which involve prolonged close-up viewing. 2,3 Additionally, data from a 2025 survey released by the Republic of Korea’s Ministry of Education, indicates that 30.41% of first-grade elementary school students either currently require vision correction (such as glasses) or had an uncorrected visual acuity of 0.7 or lower in at least one eye; among first-grade middle school students, the prevalence was 66.38%, while for first-grade high school students it was 74.45%. 4

At Santen, we are committed to advancing eye health and to improving outcomes for children affected by myopia. We will continue our efforts to make this new treatment available to patients across Asia, including South Korea and other markets in the region.

References

  1. Holden B et al, Ophthalmology 2016;123(5):1036-42.
  2. Morgan IG et al, Lancet. 2012;379(9827):1739-48.
  3. Haarman A et al, Invest Ophthalmol Vis Sci. 2020;61(4):49.
  4. 2025년 학생 건강검사 표본통계 결과 (2025 Student Health Examination Survey Results)

* Santen’s Asia business region excluding Japan and China

About Santen
Santen is a global pharmaceutical company committed to advancing eye health and improving lives through better vision. Founded in 1890 in Osaka, Japan, Santen makes use of more than 135 years of experience in research and development, manufacturing, and marketing of pharmaceuticals and medical devices to help people around the globe maintain and improve their eye health. Santen focuses exclusively on eye health and its portfolio includes glaucoma, dry eye, infection, allergy, age-related macular degeneration, and myopia. Santen’s products and services are available in more than 60 countries and regions. Guided by its Core Principle “Tenki ni sanyo suru” – Exploring the secrets and mechanisms of nature in order to contribute to people’s health – Santen combines its expertise with deep patient focus to contribute to the realization of “Happiness with Vision.”
For more information, please visit https://www.santen.com/en.

For media inquiries:
Santen Pharmaceutical Co., Ltd.
Corporate Communications
E-mail: communication@santen.com